

## **Pharmacy Drug Policy Checklist**

POLICY NAME Isotretinoin Oral (Absorica) POLICY # 1950P

## Criteria

Absorica	
	<ul> <li>1.1 Coverage criteria for Absorica requires documented trial with patient compliance (administration with high-fat meal) and subsequent failure, or intolerance, or contraindication to one of the following: <ul> <li>Amnesteen</li> <li>Claravis</li> <li>Myorisan</li> <li>Zenatane</li> </ul> </li> </ul>
	1.2 An electronic Managed Dose Limit (MDL) is in place that allows for up to 8 months of treatment
	<ul> <li>1.3 Provider can submit medical chart documentation to support medical necessity of extended treatment duration beyond the covered 8 months.</li> <li>• Maximum covered cumulative treatment dose 150mg/kg</li> <li>• Recommended treatment duration is 4 to 6 months</li> </ul>
Subsequent Treatment Courses	
	2.1 Subsequent courses of isotretinoin will not be approved until the member is at least 5

months post- treatment from the previous treatment cycle